NCT07123441 2025-08-14
A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer
Fudan University
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT05277766 2025-07-01
PIPAC-NAL-IRI
University Hospital, Ghent
Phase 1 Recruiting
NCT05854498 2025-06-12
Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer
University of Wisconsin, Madison
Phase 2 Active not recruiting
NCT03368963 2025-01-07
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
Emory University
Phase 1/2 Active not recruiting
NCT06405139 2024-11-29
Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06341296 2024-08-12
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
West China Hospital
Phase 2 Recruiting
NCT06341309 2024-08-09
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
West China Hospital
Phase 1/2 Not yet recruiting
NCT06443307 2024-06-05
Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan
Peking University
Recruiting
NCT06434090 2024-05-30
Liposomal Irinotecan Plus Bevacizumab in Irinotecan-refractory Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 1/2 Not yet recruiting
NCT03337087 2024-05-17
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
Phase 1/2 Active not recruiting
NCT06225622 2024-03-19
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Phase 1 Recruiting
NCT06192680 2024-01-18
Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT04088786 2022-05-06
Phase I Trial HIPEC With Nal-irinotecan
Stony Brook University
Phase 1 Completed
NCT01770353 2019-11-27
MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Ipsen
Phase 1 Completed
NCT02785068 2017-01-11
Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Merrimack Pharmaceuticals
Phase 1/2 Withdrawn